Aldesleukin (Proleukin)
Other Medications · Approved since 1992
Description
Aldesleukin is a recombinant interleukin-2 (IL-2) immunotherapy agent that stimulates T-cell proliferation and activation to enhance the body's immune response against cancer cells. In colorectal cancer, it is used as part of combination immunotherapy regimens, particularly with checkpoint inhibitors like PD-1 antibodies, and in adoptive cell therapy protocols using tumor-infiltrating lymphocytes (TILs). The drug serves to amplify the immune system's ability to recognize and destroy colorectal cancer cells, especially in patients with microsatellite stable (MSS) tumors that typically respond poorly to checkpoint inhibitors alone.
Mechanism of Action
Aldesleukin binds to the IL-2 receptor on T-cells and natural killer (NK) cells, triggering intracellular signaling cascades that promote cell division, survival, and cytotoxic function. This leads to expansion of tumor-reactive lymphocytes and enhanced production of inflammatory cytokines that can directly attack cancer cells and recruit additional immune effector cells to the tumor microenvironment.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Proleukin |
| Category | Other Medications |
 Status | FDA Approved |
 EMA Status | Not submitted to EMA |
 Spain Access | Not funded other indication |
| Administration | IV |
| Year Approved | 1992 |
| Clinical Trials | 30 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.